Currently, the primary pharmacological interventions for HER-2 positive breast cancer include anthracyclines, paclitaxel (Schneeweiss et al., 2015), aromatase inhibitors (Ellis et al., 2001), and other related medications. The gene discussed is CYP19A1; the disease is breast carcinoma.